Glucose Administration Route May Affect Growth Hormone Suppression and Acromegaly Diagnosis

Could Glucose Administration Routes Influence GH Secretion?

Researchers have found that intravenous glucose administration may not suppress growth hormone (GH) as effectively as oral glucose, potentially impacting diagnostic protocols for acromegaly. The small study of 12 healthy individuals revealed that IV glucose triggered a paradoxical early rise in GH levels followed by consistently higher GH concentrations compared to oral administration, with two subjects failing to meet standard suppression thresholds used to rule out acromegaly when glucose was administered intravenously.

The investigation, registered as NCT02005978, compared GH suppression during a standard oral glucose tolerance test (OGTT) with an isoglycaemic intravenous glucose infusion, maintaining identical glucose profiles between the two administration routes. GH dynamics differed significantly despite identical blood glucose levels, with the most pronounced divergence occurring at the 45-minute mark. During IV glucose infusion, GH levels initially increased by 46% at 20 minutes, while oral glucose administration resulted in a 17% decrease during the same period. The research team also documented markedly different responses in insulin, GLP-1, and GIP levels between the two administration methods, with oral glucose triggering significantly higher concentrations of these hormones compared to IV administration. These findings challenge the conventional understanding of glucose-mediated GH suppression, which has been primarily attributed to glucose-stimulated hypothalamic somatostatin release. The researchers note that their observations suggest alternative or additional mechanisms may be involved in modulating the GH response to glucose. While the exact mechanism remains unclear, the study proposes that gastrointestinal and pancreatic hormones released during oral glucose administration might contribute to the enhanced GH-suppressive effect seen with this route. The early divergence in GH levels coincided with significant differences in insulin, GLP-1, and GIP concentrations between the two administration methods. This observation is particularly intriguing given recent evidence that GLP-1 receptor agonists can actually stimulate GH secretion, contrary to what might be expected based on the current findings. The authors acknowledge that the absence of ghrelin measurements represents a significant limitation, as differences in ghrelin suppression between oral and IV glucose administration could potentially explain the observed variations in GH dynamics.

Do These Findings Challenge Acromegaly Diagnostic Protocols?

The study's findings have potential implications for acromegaly diagnosis, which relies heavily on documenting inadequate GH suppression during an OGTT. Current guidelines establish a nadir GH threshold of less than 0.4 µg/L during OGTT to exclude acromegaly. However, if IV glucose administration results in less effective GH suppression in some individuals, as suggested by this study, the diagnostic specificity of GH suppression tests might need reconsideration. "Route of glucose exposure might influence the suppressive effect of glucose on GH secretion. The potential mechanism behind remains elusive but changes in other hormones might be of importance," the researchers concluded in their report. The small sample size represents a notable limitation, as acknowledged by the investigators, particularly given the substantial inter-individual variability in GH secretion and the pronounced intra-individual variation observed between test days. This variability is visually apparent in the error bars of the GH response curves presented in the study. Additionally, the researchers noted that stress responses related to IV administration procedures could potentially contribute to transient elevations in GH levels, although they considered this unlikely to fully explain the observed differences.

How Do These Results Compare With Prior Research?

These findings build upon previous research in this area. A study by Aydin and colleagues had similarly reported higher GH nadirs during IV glucose administration compared to oral administration, though their methodology differed by using a single IV glucose bolus rather than an isoglycaemic infusion. Nakagawa and colleagues also examined GH suppression after both oral and IV glucose but reported only baseline and 150-minute values without statistical comparison. The current study improves upon these prior investigations by carefully matching glucose profiles between the two administration routes, allowing for more direct comparison of the resulting hormonal responses. The researchers emphasize the need for further studies with larger sample sizes and additional hormone measurements, particularly ghrelin, to elucidate the mechanisms underlying their observations. Future investigations might also explore the effects of incretin hormone infusions to clarify potential causal relationships between these gut-derived peptides and GH regulation.

What Are the Implications for Therapeutic Innovation?

For pharmaceutical companies developing therapies targeting incretin pathways, these findings highlight the complex interplay between glucose metabolism, gut hormones, and pituitary function. The observation that GH dynamics differ based on the route of glucose administration suggests that systemic drug delivery methods could potentially influence hormonal outcomes in ways not predicted by conventional understanding of these pathways. This complexity may need consideration in both drug development and clinical trial design, particularly for compounds targeting metabolic disorders with potential effects on multiple endocrine axes. The study also raises questions about the interpretation of diagnostic tests for acromegaly and potentially other endocrine disorders, suggesting that standardization of administration routes and careful consideration of hormonal cross-talk may be important for accurate diagnosis and treatment monitoring.

Industry Context: This research emerges amid growing interest in the multifaceted roles of gut hormones beyond glucose homeostasis. As pharmaceutical companies continue developing GLP-1 receptor agonists and related compounds for diabetes, obesity, and potentially other indications, understanding these complex hormonal interactions becomes increasingly important. The findings highlight how traditional diagnostic paradigms in endocrinology may require refinement as our understanding of hormone physiology advances, potentially creating opportunities for companies developing more sophisticated diagnostic tools and protocols for endocrine disorders.

Summary

A small study involving 12 healthy participants has revealed that intravenous glucose administration may suppress growth hormone (GH) less effectively than oral glucose, with potential implications for acromegaly diagnosis. Researchers compared GH suppression during a standard oral glucose tolerance test (OGTT) with an isoglycaemic intravenous glucose infusion, maintaining identical glucose profiles between both routes. Despite identical blood glucose levels, GH dynamics differed significantly, with IV glucose triggering a paradoxical early rise in GH levels followed by consistently higher GH concentrations compared to oral administration. Two subjects failed to meet standard suppression thresholds used to exclude acromegaly when glucose was given intravenously. The study documented markedly different responses in insulin, GLP-1, and GIP levels between the two administration methods, with oral glucose triggering significantly higher concentrations of these hormones. These findings challenge the conventional understanding that glucose-mediated GH suppression is primarily due to glucose-stimulated hypothalamic somatostatin release, suggesting that gastrointestinal and pancreatic hormones released during oral glucose administration might contribute to the enhanced GH-suppressive effect. The research has potential implications for acromegaly diagnostic protocols, which rely heavily on documenting inadequate GH suppression during an OGTT, and highlights the complex interplay between glucose metabolism, gut hormones, and pituitary function. The researchers emphasize the need for larger studies with additional hormone measurements to elucidate the mechanisms underlying their observations.